Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11724348 | 0.90 | ADORA1 (0.57) | PDE4BADORA1KMT2ANR3C1MEN1 | |
| SCHEMBL17963376 | 0.90 | NR3C1 (0.61) | PDE4BKMT2ASMN1; SMN2NR3C1MEN1 | |
| SCHEMBL587425 | 0.88 | PDE4B (0.60) | PDE4BADORA1KMT2ASMN1; SMN2NR3C1 | |
| SCHEMBL4341887 | 0.88 | PDE4B (0.62) | PDE4BADORA1KMT2ASMN1; SMN2 | |
| SCHEMBL17963171 | 0.87 | NR3C1 (0.63) | PDE4BADORA1KMT2ANR3C1MEN1 | |
| SCHEMBL6289931 | 0.86 | PDE4B (0.70) | PDE4BADORA1 | |
| SCHEMBL582528 | 0.86 | PDE4B (0.65) | PDE4BKMT2ANR3C1MEN1 | |
| SCHEMBL4339575 | 0.83 | PDE4B (0.61) | PDE4BKMT2ASMN1; SMN2NR3C1MEN1 | |
| SCHEMBL9838429 | 0.81 | PDE4B (0.58) | PDE4BKMT2A | |
| SCHEMBL16343464 | 0.81 | SMN1; SMN2 (0.55) | PDE4BADORA1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560974-B1 | PYRRAZOLOPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-01-27 | — | — | EP | disclosed |
| US-8487102-B2 | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2560974-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131571-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, GRIN3A, TACR1 | PDE4B 2258/4885ADORA1 113/4885KMT2A 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.